CRISPR & Sirius Therapeutics Announce Novel siRNA Therapies
CRISPR Therapeutics and Sirius Therapeutics have partnered to develop and commercialize SRSD107, a long-acting siRNA therapy for thromboembolic disorders....
CRISPR Therapeutics and Sirius Therapeutics have partnered to develop and commercialize SRSD107, a long-acting siRNA therapy for thromboembolic disorders....
BridgeBio Pharma released data from its Phase 3 ATTRibute-CM trial of acoramidis, showing a link between early, sustained increases...
Kymera Therapeutics announced preclinical data for KT-621, an oral STAT6 degrader, showing its potential as a once-daily treatment for...
The Coalition to Transform Clinical Trial Engagement (CTCTE) launched the Champions for Change – Paid Time Off (PTO) Initiative...
NovelMed’s Ruxoprubart, a novel complement-targeting immunotherapy, has shown positive interim results in a Phase II trial for Paroxysmal Nocturnal...
Prime Medicine announced positive initial clinical trial data for PM359, a prime-edited cell therapy for Chronic Granulomatous Disease (CGD)....
SELLAS Life Sciences Group announced the first pediatric patient with acute myeloid leukemia (AML) has been dosed in a...
Excision BioTherapeutics announced preclinical data demonstrating the efficacy of EBT-107, a CRISPR-based gene therapy candidate for chronic hepatitis B...
Pacira BioSciences announced preliminary data suggesting that pre-existing and treatment-induced antibodies do not impact the safety and efficacy of...
Voyager Therapeutics published data in Molecular Therapy demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV...